CN101957363A - Sample treatment fluid for latex immunoturbidimetry detection - Google Patents
Sample treatment fluid for latex immunoturbidimetry detection Download PDFInfo
- Publication number
- CN101957363A CN101957363A CN2010102787066A CN201010278706A CN101957363A CN 101957363 A CN101957363 A CN 101957363A CN 2010102787066 A CN2010102787066 A CN 2010102787066A CN 201010278706 A CN201010278706 A CN 201010278706A CN 101957363 A CN101957363 A CN 101957363A
- Authority
- CN
- China
- Prior art keywords
- sample treatment
- treatment solution
- buffering agent
- latex immunoturbidimetry
- ionics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004816 latex Substances 0.000 title claims abstract description 24
- 229920000126 latex Polymers 0.000 title claims abstract description 24
- 239000012530 fluid Substances 0.000 title claims abstract description 11
- 238000001514 detection method Methods 0.000 title claims abstract description 7
- 229920001503 Glucan Polymers 0.000 claims abstract description 10
- 239000000872 buffer Substances 0.000 claims abstract description 5
- 150000003626 triacylglycerols Chemical class 0.000 claims description 16
- 239000006172 buffering agent Substances 0.000 claims description 12
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 9
- 238000013016 damping Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- GYRVPKXEKRPIGJ-UHFFFAOYSA-N ethanesulfonate;quinolin-1-ium Chemical compound CCS([O-])(=O)=O.[NH+]1=CC=CC2=CC=CC=C21 GYRVPKXEKRPIGJ-UHFFFAOYSA-N 0.000 claims description 4
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- DEQXHPXOGUSHDX-UHFFFAOYSA-N methylaminomethanetriol;hydrochloride Chemical compound Cl.CNC(O)(O)O DEQXHPXOGUSHDX-UHFFFAOYSA-N 0.000 claims description 4
- 210000001268 chyle Anatomy 0.000 abstract description 7
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 239000002736 nonionic surfactant Substances 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 description 6
- 238000005352 clarification Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011096 sample clarification Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to sample treatment fluid for latex immunoturbidimetry detection, which comprises triglycercide ethoxylate, a nonionic surfactant, glucan (20 thousands) and a buffer. The invention solves the problem that latex immunoturbidimetry can not be adopted for detection because the sample treatment fluid in the traditional reagent has poor effect of eliminating high-degree chyle or turbidity phenomenon of a sample.
Description
Technical field
The invention belongs to the medical science detection and use the sample treatment solution field, particularly relate to a kind of latex immunoturbidimetry detection sample treatment solution.
Technical background
The detectable of latex immunoturbidimetry is widely used in the clinical examination field detecting the immunoassays of antigen in the sample or antibody.But when running into the clinical sample of height chyle or muddiness, the sample treatment solution in the available reagent is bad for the height chyle or the turbid phenomenon elimination effect of sample, thereby causes can't adopting the latex immunoturbidimetry to detect because of the sample blank value is too high.
Summary of the invention
The purpose of this invention is to provide a kind of latex immunoturbidimetry and detect the sample change clarification of using sample treatment solution, described sample preparation liquid can make height chyle or muddiness.Solved clinically and eliminated the bad problem that can't adopt the latex immunoturbidimetry to detect of effect for the height chyle or the turbid phenomenon of sample because of the sample treatment solution in the available reagent.
To achieve these goals, the technical solution used in the present invention is: the latex immunoturbidimetry detects and uses sample treatment solution, comprises following composition: ethoxylated triglycerides, non-ionics, glucosan 20,000, buffering agent.Its hydrophilic hydrophobic balance value of described ethoxylated triglycerides is 6.Described non-ionics is Qu Latong 100 or polysorbas20.Described buffering agent is any one in phosphate buffer, 4-hydroxyethyl piperazine ethanesulfonic acid damping fluid, 2-sign indicating number quinoline ethyl sulfonic acid damping fluid, the trishydroxymethylaminomethane hydrochloride buffer.The content that the latex immunoturbidimetry detects with each composition of sample treatment solution is: the buffering agent of (1) 0.3～3% ethoxylated triglycerides, (2) 0.05～3% non-ionics, glucosan 20,000, (4) 0.02～0.5mol/L of (3) 0.02～2%.
Chyle or muddiness easily become when increasing because of the hdl particle that is rich in triglyceride in the blood plasma, the present invention has added ethoxylated triglycerides in sample preparation liquid, ethoxylated triglycerides can dissolve the hdl particle that is rich in triglyceride, makes sample to be checked become clarification.When the hydrophilic hydrophobic balance value of ethoxylated triglycerides is 6, content be 0.3～3% o'clock better.But independent ethoxylated triglycerides can not be dissolved in the buffering agent, therefore needs to add at least a non-ionic surfactant and promotes its dissolving.Non-ionics can be Qu Latong 100 or polysorbas20, and its content is neither to influence the latex immunoturbidimetry at 0.05～3% o'clock to measure and 0.3～3% ethoxylated triglycerides can be dissolved fully again.Glucosan 20,000 in the sample preparation liquid also works to quicken the ethoxylated triglycerides dissolving, content be 0.02～2% o'clock better.Buffering agent is any one in phosphate buffer, 4-hydroxyethyl piperazine ethanesulfonic acid damping fluid, 2-sign indicating number quinoline ethyl sulfonic acid damping fluid, the trishydroxymethylaminomethane hydrochloride buffer, the pH value of sample treatment solution can be controlled in 6～8 the scope, content is advisable with 0.02～0.5mol/L, is beneficial to the carrying out of latex immunoturbidimetry reaction.
The advantage that latex immunoturbidimetry from the above of the present invention detects with sample treatment solution is that sample preparation liquid can make height chyle or muddy sample become clarification, has solved problems of the prior art.
Embodiment
The latex immunoturbidimetry detects and uses sample treatment solution, and comprise following composition: (1) 1%, hydrophilic hydrophobic balance value is 6 ethoxylated triglycerides, (2) 0.1% polysorbas20, (3) 0.04% glucosan 20,000, the phosphate buffer of (4) 0.05mol/L.
Get the piarhemia sample and the normal blood of 20 μ L muddinesses respectively, each adds 800 μ L sample preparation liquid and mixes, after leaving standstill 10 seconds, detect the background level of two samples with the specific protein analyser, the result shows that two background levels are identical, i.e. Hun Zhuo piarhemia sample clarification fully after sample preparation liquid is handled.
Claims (9)
1. the latex immunoturbidimetry detects and uses sample treatment solution, it is characterized in that comprising following composition: ethoxylated triglycerides, non-ionics, glucosan 20,000, buffering agent.
2. detect according to the described latex immunoturbidimetry of claim 1 and use sample treatment solution, it is characterized in that its hydrophilic hydrophobic balance value of described ethoxylated triglycerides is 6.
3. use sample treatment solution according to claim 1 or 2 described latex immunoturbidimetries detections, it is characterized in that described non-ionics is Qu Latong 100 or polysorbas20.
4. use sample treatment solution according to claim 1 or 2 described latex immunoturbidimetries detections, it is characterized in that described buffering agent is any one in phosphate buffer, 4-hydroxyethyl piperazine ethanesulfonic acid damping fluid, 2-sign indicating number quinoline ethyl sulfonic acid damping fluid, the trishydroxymethylaminomethane hydrochloride buffer.
5. detect according to the described latex immunoturbidimetry of claim 3 and use sample treatment solution, it is characterized in that described buffering agent is any one in phosphate buffer, 4-hydroxyethyl piperazine ethanesulfonic acid damping fluid, 2-sign indicating number quinoline ethyl sulfonic acid damping fluid, the trishydroxymethylaminomethane hydrochloride buffer.
6. detect according to claim 1 or 2 described latex immunoturbidimetries and use sample treatment solution, it is characterized in that the content of each composition is: the buffering agent of (1) 0.3～3% ethoxylated triglycerides, (2) 0.05～3% non-ionics, glucosan 20,000, (4) 0.02～0.5mol/L of (3) 0.02～2%.
7. detect according to the described latex immunoturbidimetry of claim 3 and use sample treatment solution, it is characterized in that the content of each composition is: the buffering agent of (1) 0.3～3% ethoxylated triglycerides, (2) 0.05～3% non-ionics, glucosan 20,000, (4) 0.02～0.5mol/L of (3) 0.02～2%.
8. detect according to the described latex immunoturbidimetry of claim 4 and use sample treatment solution, it is characterized in that the content of each composition is: the buffering agent of (1) 0.3～3% ethoxylated triglycerides, (2) 0.05～3% non-ionics, glucosan 20,000, (4) 0.02～0.5mol/L of (3) 0.02～2%.
9. detect according to the described latex immunoturbidimetry of claim 5 and use sample treatment solution, it is characterized in that the content of each composition is: the buffering agent of (1) 0.3～3% ethoxylated triglycerides, (2) 0.05～3% non-ionics, glucosan 20,000, (4) 0.02～0.5mol/L of (3) 0.02～2%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102787066A CN101957363A (en) | 2010-09-13 | 2010-09-13 | Sample treatment fluid for latex immunoturbidimetry detection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102787066A CN101957363A (en) | 2010-09-13 | 2010-09-13 | Sample treatment fluid for latex immunoturbidimetry detection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101957363A true CN101957363A (en) | 2011-01-26 |
Family
ID=43484814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102787066A Pending CN101957363A (en) | 2010-09-13 | 2010-09-13 | Sample treatment fluid for latex immunoturbidimetry detection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101957363A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102628868A (en) * | 2011-12-30 | 2012-08-08 | 北京九强生物技术股份有限公司 | Latex enhanced immunoturbidimetry kit for detection of asymmetric dimethylarginine content |
| CN103698525A (en) * | 2014-01-09 | 2014-04-02 | 北京万泰德瑞诊断技术有限公司 | Latex immunoturbidimetry pepsinogen I detection kit for eliminating chyle interference |
| CN105067815A (en) * | 2015-09-16 | 2015-11-18 | 浙江凯成生物科技有限公司 | Kit for measuring pepsinogen I/II content of human serum |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS582660A (en) * | 1981-06-30 | 1983-01-08 | Chugai Pharmaceut Co Ltd | Immunological reagent |
| JPS59220646A (en) * | 1983-05-30 | 1984-12-12 | Green Cross Corp:The | Aqueous solvent for aggregation test |
| JPS6125062A (en) * | 1984-07-13 | 1986-02-03 | Nitsusui Seiyaku Kk | Measurement of aso value by immunonephelometry |
| CN1372144A (en) * | 2001-02-19 | 2002-10-02 | 奥林匹斯诊断有限公司 | Reagent for eliminating biological specimen turbidness |
| CN1507564A (en) * | 2001-12-27 | 2004-06-23 | ���µ�����ҵ��ʽ���� | Method for measuring immune response and kit for measuring immune response used in the method |
| CN1545420A (en) * | 2001-08-20 | 2004-11-10 | ˹��ά˹��ҽҩ����˾ | Topical composition, topical composition precursor, and methods for manufacturing and using |
| CN101266244A (en) * | 2007-03-15 | 2008-09-17 | 爱芙乐赛制药株式会社 | Settlement inhibiting method of tiny particle for binding reactive substance and the reagent |
-
2010
- 2010-09-13 CN CN2010102787066A patent/CN101957363A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS582660A (en) * | 1981-06-30 | 1983-01-08 | Chugai Pharmaceut Co Ltd | Immunological reagent |
| JPS59220646A (en) * | 1983-05-30 | 1984-12-12 | Green Cross Corp:The | Aqueous solvent for aggregation test |
| JPS6125062A (en) * | 1984-07-13 | 1986-02-03 | Nitsusui Seiyaku Kk | Measurement of aso value by immunonephelometry |
| CN1372144A (en) * | 2001-02-19 | 2002-10-02 | 奥林匹斯诊断有限公司 | Reagent for eliminating biological specimen turbidness |
| CN1545420A (en) * | 2001-08-20 | 2004-11-10 | ˹��ά˹��ҽҩ����˾ | Topical composition, topical composition precursor, and methods for manufacturing and using |
| CN1507564A (en) * | 2001-12-27 | 2004-06-23 | ���µ�����ҵ��ʽ���� | Method for measuring immune response and kit for measuring immune response used in the method |
| CN101266244A (en) * | 2007-03-15 | 2008-09-17 | 爱芙乐赛制药株式会社 | Settlement inhibiting method of tiny particle for binding reactive substance and the reagent |
Non-Patent Citations (1)
| Title |
|---|
| 唐伟国: "《医学检验诊断试剂的制备与应用》", 31 October 1996, 上海科学技术文献出版社 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102628868A (en) * | 2011-12-30 | 2012-08-08 | 北京九强生物技术股份有限公司 | Latex enhanced immunoturbidimetry kit for detection of asymmetric dimethylarginine content |
| CN102628868B (en) * | 2011-12-30 | 2014-09-17 | 北京九强生物技术股份有限公司 | Latex enhanced immunoturbidimetry kit for detection of asymmetric dimethylarginine content |
| CN103698525A (en) * | 2014-01-09 | 2014-04-02 | 北京万泰德瑞诊断技术有限公司 | Latex immunoturbidimetry pepsinogen I detection kit for eliminating chyle interference |
| CN103698525B (en) * | 2014-01-09 | 2015-10-14 | 北京万泰德瑞诊断技术有限公司 | Latex immunoturbidimetry pepsinogen I detection kit for eliminating chyle interference |
| CN105067815A (en) * | 2015-09-16 | 2015-11-18 | 浙江凯成生物科技有限公司 | Kit for measuring pepsinogen I/II content of human serum |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104198724B (en) | Fibrin or fibrinogen degradation product (FDP) detection kit | |
| CN102252987B (en) | Method for detecting protein content | |
| CN104360056B (en) | A kind of method that promotes the sensitivity of latex enhancing immune turbidimetry | |
| WO2018001215A1 (en) | Kit for detecting bacterial vaginosis | |
| CN104316692B (en) | A kind of neonate total galactose detection kit, its using method and preparation method | |
| CN107741493A (en) | A kind of kit using Immune competition turbidimetry for Determination microdose urine protein | |
| US20150301037A1 (en) | Use of diazolidinyl urea for anti-clumping of biological samples | |
| CN106290907B (en) | Serum amyloid A protein quantitative detecting reagent and detection method in whole blood | |
| CN102243241A (en) | A homogeneous sol particle-type neutrophil gelatinase-associated lipocalin assay kit and preparation method thereof | |
| Akcay et al. | The real and apparent plasma oxalate | |
| CN101957363A (en) | Sample treatment fluid for latex immunoturbidimetry detection | |
| WO2019075769A1 (en) | Method for detecting hypersensitive c-reactive protein | |
| CN102368071B (en) | Chemiluminescent immunoassay kit for detecting mycoplasma pneumoniae IgM antibody | |
| Soliman et al. | Significance of the hepatitis C virus core antigen testing as an alternative marker for hepatitis diagnosis in Egyptian patients. | |
| CN103926405A (en) | Creatine kinase isozyme detection kit and preparation thereof | |
| CN104049090B (en) | A kind of test kit detecting alanylamino peptase | |
| CN103675297A (en) | Medicament-induced hemolytic anemia detection kit and detection method thereof | |
| CN102192985A (en) | Human beta-amyloid kit | |
| CN106596535A (en) | Blood uric acid detection test paper | |
| CN101226152A (en) | Automatic analysis method and liquid stabilising agent for blood serum total ferro combining ability | |
| CN102368068B (en) | Kit for detecting chlamydia pneumoniae IgM antibody | |
| CN104561237A (en) | Blood ammonia kit | |
| CN101942498A (en) | Kit for rapidly detecting diabetes | |
| CN104698159B (en) | A kind of detection method of endotoxin content | |
| JP6358942B2 (en) | Reagent for measuring endotoxin and method for measuring endotoxin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110126 |